Synaptogenix (NASDAQ:TAOX) Shares Down 3.4% – What’s Next?

Synaptogenix, Inc. (NASDAQ:TAOX) dropped 3.4% on Tuesday . The company traded as low as $3.56 and last traded at $3.72. Approximately 68,949 shares traded hands during mid-day trading, a decline of 52% from the average daily volume of 142,797 shares. The stock had previously closed at $3.85.

Analyst Ratings Changes

A number of research firms recently commented on TAOX. Weiss Ratings restated a “sell (d-)” rating on shares of Synaptogenix in a report on Tuesday, April 21st. Wall Street Zen raised shares of Synaptogenix from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Synaptogenix Stock Up 4.7%

The company has a 50-day moving average price of $4.92 and a 200-day moving average price of $5.00. The company has a market capitalization of $28.54 million, a price-to-earnings ratio of -0.29 and a beta of 1.41.

Synaptogenix (NASDAQ:TAOX) last announced its quarterly earnings data on Wednesday, May 13th. The company reported $0.43 earnings per share (EPS) for the quarter. The company had revenue of $5.96 million during the quarter.

About Synaptogenix

Synaptogenix, Inc operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer’s disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University.